Showing results (2331-2340 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|December 7, 2017
Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility AnalysisRebekah Fong Soe Khioe, Chris Skedgel, Andrew Hart, et al.
Pharmacoeconomics|December 8, 2017
Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA AgenciesAmr Makady, Ard van Veelen, Páll Jonsson, et al.
Pharmacoeconomics|December 11, 2017
Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature ReviewLazaros Andronis, Ilias Goranitis, Sue Bayliss, et al.
Pharmacoeconomics|December 13, 2017
Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims DatabasesMargret V Bjarnadottir, David Czerwinski, Eberechukwu Onukwugha
Pharmacoeconomics|November 28, 2017
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Ahmed Abdulla, Adrian Bagust, et al.
Pharmacoeconomics|December 22, 2017
Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in ChildrenTosin Lambe, Emma Frew, Natalie J Ives, et al.
Pharmacoeconomics|March 3, 2018
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in EnglandIrina A Tikhonova, Nicola Huxley, Tristan Snowsill, et al.
Pharmacoeconomics|March 5, 2018
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalShijie Ren, Iñigo Bermejo, Emma Simpson, et al.
Pharmacoeconomics|March 1, 2018
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung CancerJosh J Carlson, Kangho Suh, Panos Orfanos, et al.
Pharmacoeconomics|June 14, 2012
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centreMareike Heimeshoff, Helge Hollmeyer, Jonas Schreyögg, et al.
Pageof 336